Objective: The objective of present clinical report was to highlight importance of early identification of adverse drug reactions (ADRs) in the patients who have taken dapagliflozin during the treatment of type-2 diabetes. Case presentation: A 58years old female patient having body weight 49 kg, a known case of type-2 diabetes (Since 8 years) visited the outpatient department at the tertiary care hospital on 1st June, 2022, with the complaints of uncontrolled diabetes (since 3 year) along with lower limb pain . Patient was evaluated, investigated by the consultant .After taking of medication patient started loose motion/ diarrhea 8- 10 episodes on 2nd June, 2022. The risk of developing loose motion/diarrhea while taking of dapagliflozin with certain factors such as advance age, drug- drug interaction, genetic polymorphism and gender. Conclusion: This case highlights the need of monitoring of dapagliflozin treatment in clinics and hospitals. The use of risk stratification tool to identify the risk of patients and also need for self monitoring by the patients.